Home / Healthcare / Acquired Hemophilia Treatment Market By Type (Hemophilia A, Hemophilia B, Hemophilia C and Others), By Treatment (On-Demand and Prophylaxis), By Therapeutic Areas (Replacement Therapy, Gene Therapy, Immune Tolerance Induction Therapy and Others), By Type of End Users (Hospitals, Clinics and Others) – Growth, Future prospects & Competitive Analysis 2021-2029

Acquired Hemophilia Treatment Market By Type (Hemophilia A, Hemophilia B, Hemophilia C and Others), By Treatment (On-Demand and Prophylaxis), By Therapeutic Areas (Replacement Therapy, Gene Therapy, Immune Tolerance Induction Therapy and Others), By Type of End Users (Hospitals, Clinics and Others) – Growth, Future prospects & Competitive Analysis 2021-2029


Published: Jun 2021

The Acquired Hemophilia Treatment Market is anticipated to grow at a compound annual growth rate of 3.3% for the forecast period of 2021 to 2029. This growth is mainly fueled by rising rate of prophylaxis treatment among patients. This report covers all the quantitative and qualitative aspects of the Acquired Hemophilia Market and also talks about its key drivers, the challenges it faces, the growth opportunities present in the market, and its future prospects.

Acquired Hemophilia Treatment Market: Overview

Acquired Hemophilia (AH) is a rare auto-immune bleeding condition that severely impairs the body's capacity to form a clot during the event of a hemorrhage that arises in people with no family history of diseases related to clotting or coagulation. The body produces inhibitors (antibodies) that target clotting factors, most commonly factor VIII, in Acquired Hemophilia. Clotting factors are specialized proteins that are needed for normal blood clotting. Eventually, affected people develop disorders related to severe bleeding into the muscles, skin and soft tissues. AH, at times is also related to medical conditions such as cancer, tumors and pregnancy other than rheumatoid arthritis, ulcerative colitis, and psoriasis.

Acquired Hemophilia Treatment Market

The market has been categorized and sub-categorized on basis of Type, Treatment, Therapeutic Areas, End Users and Regional Basis. While viewing this market on the basis of Type, Hemophilia A presides the market share by 50%-60% and is the most severe type whereas Hemophilia B only constitutes 20% of the market share.

Increasing Prevalence of AH among New Born Demands Effective Treatment

The key compelling factors of this market are increasing prevalence of Acquired Hemophilia in newborn, rising diagnostic rates, Increase in use of Prophylactic treatment, rising awareness among people, rising number of auto-immune diseases and beneficial reimbursement policies. Generally, AH is found in old age population and has a mortality rate of 21%, if not treated. Hemophilia A, is the most severe and commonly found type of Acquired Hemophilia. The challenges faced by AH Treatment Market are: high cost of treatment hindering penetration in low and middle income countries, lack of availability and accessibility of new drugs and adoption rate of technologically advanced products is low.

Healthcare Infrastructure in NA Offers Effective Access to Therapeutic Options

On the basis of regional segmentation, Acquired Hemophilia Treatment Market includes North America, Latin America, Europe, Asia Pacific, Middle East and Africa, and Rest of the World.  North America dominates the AH Treatment Market in 2020. The key drivers of this market in North America have been U.S. people getting diagnosed at young age, growing awareness among people, better medical health facilities, the favorable reimbursement scenario for medicines prescribed for the treatment of acquired hemophilia further strengthens the region's market development. The European Medical Agency (EMA) created a supportive regulatory climate by authorizing FastTrack classification for drug discovery and production of medicines for treating acquired hemophilia, putting Europe in second place. Key Players ruling this market are: Baxter Healthcare Corporation, Biogen, Sanofi, Shire (Baxalta), CSL Behring, Pfizer, Inc., Bayer AG, Ferring Pharmaceuticals, Spark Therapeutics Inc., F. HOFFMAN LA ROCHE, Sanofi, Genentech, Inc., Novo Nordisk, GlaxoSmithKline Plc, and Bristol-Myers Squibb. Industry leaders are targeting on developing Research and Development activities, new product launches.

Historical & Forecast Period 

This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment are calculated for the forecast period from 2021 to 2029

Report Scope by Segments 

Market revenues and CAGR were derived from primary and secondary research. Both quantitative and qualitative trends were considered for extrapolation of market revenues. The derived market estimates were further validated from top down, bottom strategies and primary research. The scope of the market is limited to the following segments of product categories and region.

ATTRIBUTE DETAILS

Research Period

 2019-2029

Base Year

 2020

Forecast Period

 2021-2029

Historical Year

 2019

Unit

 US$ Million

Segmentation

 Type Segment (2019-2029; US$ Mn)

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others

 Treatment Segment (2019-2029; US$ Mn)

  • On-Demand
  • Prophylaxis

 Therapeutic Areas (2019-2029; US$ Mn)

  • Replacement Therapy
  • Gene Therapy
  • Immune Tolerance Induction Therapy
  • Others

 End-User (2019-2029; US$ Mn)

  • Hospitals
  • Clinics
  • Others

 Region type Segment (2019-2029; US$ Mn)

  • North America
    • U.S.
    • Canada
  • Europe
    • United Kingdom
    • France
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Rest of the World
    • Latin America
    • Middle East and Africa

 Global Impact of Covid-19 Segment (2020-2021; US$ Mn)

  • Pre Covid-19 situation
  • Post Covid-19 situation

TABLE 1 Global Acquired Hemophilia Treatment Market, By Type (US$ Mn), 2019 - 2029
TABLE 2 Global Acquired Hemophilia Treatment Market, By Treatment (US$ Mn), 2019 - 2029
TABLE 3 Global Acquired Hemophilia Treatment Market, By Therapeutic Areas (US$ Mn), 2019 - 2029
TABLE 4 Global Acquired Hemophilia Treatment Market, By End Users (US$ Mn), 2019 - 2029
TABLE 5 Global Acquired Hemophilia Treatment Market (US$ Mn), by Geography, 2019 - 2029
TABLE 6 North America Acquired Hemophilia Treatment Market (US$ Mn), by Country, 2019 - 2029
TABLE 7 Europe Acquired Hemophilia Treatment Market (US$ Mn), by Country, 2019 - 2029
TABLE 8 Asia-Pacific Acquired Hemophilia Treatment Market (US$ Mn), by Country, 2019 - 2029
TABLE 9 Latin America Acquired Hemophilia Treatment Market (US$ Mn), by Country, 2019 - 2029
TABLE 10 Middle East and Africa Acquired Hemophilia Treatment Market (US$ Mn), by Country, 2019 - 2029
TABLE 11 SWOT Analysis, by Factor for all provided regions (Political & Legal, Economic and Technological)
TABLE 12 Baxter Healthcare Corporation: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 13 Biogen: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 14 Pfizer: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 15 F. HOFFMAN LA ROCHE: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 16 Sanofi: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 17 Ferring Pharmaceuticals: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 18 Genentech, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 19 Bristol-Myers Squibb: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 20 Novo Nordisk: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 21 GlaxoSmithKline, Plc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 22 Shire (Baxalta): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 23 CSL Behring: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 24 Bayer AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 25 Spark Therapeutics Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +